Lavender essential oil inhalation suppresses allergic airway inflammation and mucous cell hyperplasia in a murine model of asthma

Tomoe Iio, Misako Shibakura, Kanayo Yokota, Michinori Aoe, Tomoko Hyoda, Ryouko Shinohata, Arihiko Kanehiro, Mitsune Tanimoto, Mikio Kataoka

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Aims Lavender essential oil (Lvn) has been reported to have anti-inflammatory effects. Bronchial asthma is characterized by bronchial allergic inflammation with airway remodeling. Therefore, we evaluated the anti-inflammatory effect of Lvn on experimentally induced bronchial asthma in a murine model. Main methods BALB/c mice were sensitized by an intraperitoneal injection of ovalbumin (OVA) at days 0 and 14, and subsequently challenged with nebulized OVA on days 28-30 (Control-Asthma group). Mice in the treatment group inhaled Lvn on days 14-31 (Lvn-Asthma group). The allergic inflammatory response was determined on days 32 and 33. Key findings An increase in airway resistance was inhibited in the Lvn-Asthma group than in the Control-Asthma group. The Lvn-Asthma group showed lower total cell numbers and eosinophils in bronchoalveolar lavage (BAL) fluids and peribronchial and perivascular tissues when compared with the Control-Asthma group. The Lvn-Asthma group also had less mucin hyperplasia than the Control-Asthma group. Furthermore, the Lvn-Asthma group showed lower interleukin (IL)-5 and IL-13 cytokine levels in BAL fluids, as well as reduced IL-4 and IL-5 mRNA expression in lung tissue, compared with the Control-Asthma group and determined by FlowCytomix and reverse transcriptase-polymerase chain reaction (RT-PCR), respectively. In addition, Lvn inhalation reduced Muc5b mRNA expression in the lungs without significantly changing the expression of Muc5ac mRNA. Significance Lvn inhibits allergic inflammation and mucous cell hyperplasia with suppression of T-helper-2 cell cytokines and Muc5b expression in a murine model of asthma. Consequently, Lvn may be useful as an alternative medicine for bronchial asthma.

Original languageEnglish
Pages (from-to)109-115
Number of pages7
JournalLife Sciences
Volume108
Issue number2
DOIs
Publication statusPublished - Jul 17 2014

Fingerprint

Volatile Oils
Inhalation
Hyperplasia
Asthma
Inflammation
Interleukin-5
Ovalbumin
Messenger RNA
Anti-Inflammatory Agents
Tissue
Cytokines
Fluids
Interleukin-13
Polymerase chain reaction
RNA-Directed DNA Polymerase
Control Groups
Mucins
Interleukin-4
Medicine
Bronchoalveolar Lavage Fluid

Keywords

  • Alternative medicine
  • Asthma
  • Cytokines
  • Lavender
  • Mucin

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Lavender essential oil inhalation suppresses allergic airway inflammation and mucous cell hyperplasia in a murine model of asthma. / Iio, Tomoe; Shibakura, Misako; Yokota, Kanayo; Aoe, Michinori; Hyoda, Tomoko; Shinohata, Ryouko; Kanehiro, Arihiko; Tanimoto, Mitsune; Kataoka, Mikio.

In: Life Sciences, Vol. 108, No. 2, 17.07.2014, p. 109-115.

Research output: Contribution to journalArticle

Iio, Tomoe ; Shibakura, Misako ; Yokota, Kanayo ; Aoe, Michinori ; Hyoda, Tomoko ; Shinohata, Ryouko ; Kanehiro, Arihiko ; Tanimoto, Mitsune ; Kataoka, Mikio. / Lavender essential oil inhalation suppresses allergic airway inflammation and mucous cell hyperplasia in a murine model of asthma. In: Life Sciences. 2014 ; Vol. 108, No. 2. pp. 109-115.
@article{e1436c966157485680968d51e94e488c,
title = "Lavender essential oil inhalation suppresses allergic airway inflammation and mucous cell hyperplasia in a murine model of asthma",
abstract = "Aims Lavender essential oil (Lvn) has been reported to have anti-inflammatory effects. Bronchial asthma is characterized by bronchial allergic inflammation with airway remodeling. Therefore, we evaluated the anti-inflammatory effect of Lvn on experimentally induced bronchial asthma in a murine model. Main methods BALB/c mice were sensitized by an intraperitoneal injection of ovalbumin (OVA) at days 0 and 14, and subsequently challenged with nebulized OVA on days 28-30 (Control-Asthma group). Mice in the treatment group inhaled Lvn on days 14-31 (Lvn-Asthma group). The allergic inflammatory response was determined on days 32 and 33. Key findings An increase in airway resistance was inhibited in the Lvn-Asthma group than in the Control-Asthma group. The Lvn-Asthma group showed lower total cell numbers and eosinophils in bronchoalveolar lavage (BAL) fluids and peribronchial and perivascular tissues when compared with the Control-Asthma group. The Lvn-Asthma group also had less mucin hyperplasia than the Control-Asthma group. Furthermore, the Lvn-Asthma group showed lower interleukin (IL)-5 and IL-13 cytokine levels in BAL fluids, as well as reduced IL-4 and IL-5 mRNA expression in lung tissue, compared with the Control-Asthma group and determined by FlowCytomix and reverse transcriptase-polymerase chain reaction (RT-PCR), respectively. In addition, Lvn inhalation reduced Muc5b mRNA expression in the lungs without significantly changing the expression of Muc5ac mRNA. Significance Lvn inhibits allergic inflammation and mucous cell hyperplasia with suppression of T-helper-2 cell cytokines and Muc5b expression in a murine model of asthma. Consequently, Lvn may be useful as an alternative medicine for bronchial asthma.",
keywords = "Alternative medicine, Asthma, Cytokines, Lavender, Mucin",
author = "Tomoe Iio and Misako Shibakura and Kanayo Yokota and Michinori Aoe and Tomoko Hyoda and Ryouko Shinohata and Arihiko Kanehiro and Mitsune Tanimoto and Mikio Kataoka",
year = "2014",
month = "7",
day = "17",
doi = "10.1016/j.lfs.2014.05.018",
language = "English",
volume = "108",
pages = "109--115",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Lavender essential oil inhalation suppresses allergic airway inflammation and mucous cell hyperplasia in a murine model of asthma

AU - Iio, Tomoe

AU - Shibakura, Misako

AU - Yokota, Kanayo

AU - Aoe, Michinori

AU - Hyoda, Tomoko

AU - Shinohata, Ryouko

AU - Kanehiro, Arihiko

AU - Tanimoto, Mitsune

AU - Kataoka, Mikio

PY - 2014/7/17

Y1 - 2014/7/17

N2 - Aims Lavender essential oil (Lvn) has been reported to have anti-inflammatory effects. Bronchial asthma is characterized by bronchial allergic inflammation with airway remodeling. Therefore, we evaluated the anti-inflammatory effect of Lvn on experimentally induced bronchial asthma in a murine model. Main methods BALB/c mice were sensitized by an intraperitoneal injection of ovalbumin (OVA) at days 0 and 14, and subsequently challenged with nebulized OVA on days 28-30 (Control-Asthma group). Mice in the treatment group inhaled Lvn on days 14-31 (Lvn-Asthma group). The allergic inflammatory response was determined on days 32 and 33. Key findings An increase in airway resistance was inhibited in the Lvn-Asthma group than in the Control-Asthma group. The Lvn-Asthma group showed lower total cell numbers and eosinophils in bronchoalveolar lavage (BAL) fluids and peribronchial and perivascular tissues when compared with the Control-Asthma group. The Lvn-Asthma group also had less mucin hyperplasia than the Control-Asthma group. Furthermore, the Lvn-Asthma group showed lower interleukin (IL)-5 and IL-13 cytokine levels in BAL fluids, as well as reduced IL-4 and IL-5 mRNA expression in lung tissue, compared with the Control-Asthma group and determined by FlowCytomix and reverse transcriptase-polymerase chain reaction (RT-PCR), respectively. In addition, Lvn inhalation reduced Muc5b mRNA expression in the lungs without significantly changing the expression of Muc5ac mRNA. Significance Lvn inhibits allergic inflammation and mucous cell hyperplasia with suppression of T-helper-2 cell cytokines and Muc5b expression in a murine model of asthma. Consequently, Lvn may be useful as an alternative medicine for bronchial asthma.

AB - Aims Lavender essential oil (Lvn) has been reported to have anti-inflammatory effects. Bronchial asthma is characterized by bronchial allergic inflammation with airway remodeling. Therefore, we evaluated the anti-inflammatory effect of Lvn on experimentally induced bronchial asthma in a murine model. Main methods BALB/c mice were sensitized by an intraperitoneal injection of ovalbumin (OVA) at days 0 and 14, and subsequently challenged with nebulized OVA on days 28-30 (Control-Asthma group). Mice in the treatment group inhaled Lvn on days 14-31 (Lvn-Asthma group). The allergic inflammatory response was determined on days 32 and 33. Key findings An increase in airway resistance was inhibited in the Lvn-Asthma group than in the Control-Asthma group. The Lvn-Asthma group showed lower total cell numbers and eosinophils in bronchoalveolar lavage (BAL) fluids and peribronchial and perivascular tissues when compared with the Control-Asthma group. The Lvn-Asthma group also had less mucin hyperplasia than the Control-Asthma group. Furthermore, the Lvn-Asthma group showed lower interleukin (IL)-5 and IL-13 cytokine levels in BAL fluids, as well as reduced IL-4 and IL-5 mRNA expression in lung tissue, compared with the Control-Asthma group and determined by FlowCytomix and reverse transcriptase-polymerase chain reaction (RT-PCR), respectively. In addition, Lvn inhalation reduced Muc5b mRNA expression in the lungs without significantly changing the expression of Muc5ac mRNA. Significance Lvn inhibits allergic inflammation and mucous cell hyperplasia with suppression of T-helper-2 cell cytokines and Muc5b expression in a murine model of asthma. Consequently, Lvn may be useful as an alternative medicine for bronchial asthma.

KW - Alternative medicine

KW - Asthma

KW - Cytokines

KW - Lavender

KW - Mucin

UR - http://www.scopus.com/inward/record.url?scp=84903886490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903886490&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2014.05.018

DO - 10.1016/j.lfs.2014.05.018

M3 - Article

C2 - 24909715

AN - SCOPUS:84903886490

VL - 108

SP - 109

EP - 115

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 2

ER -